PremiumCompany AnnouncementsHUTCHMED Announces Approval of Key Resolution at Extraordinary General Meeting Hutchmed says NDA for Tazverik granted conditional approval in China HUTCHMED Secures NMPA Approval for TAZVERIK® in China PremiumThe FlyHutchmed sees FY25 Oncology/Immunology revenue $350M-$450M Hutchmed reports FY24 EPS 22c vs. 59c last year HUTCHMED Achieves Profitability with Strong Oncology Growth and Strategic Developments PremiumCompany AnnouncementsHUTCHMED Announces EGM for Strategic Disposal Approval Hutchmed completes enrollment of fanregratinib trial HUTCHMED Appoints Alvin Wong as Independent Non-executive Director